Evaluation of IOP, Refraction, Anterior Chamber Depth, Macular Thickness and Specular Microscopy Post ND YAG Laser in Patients with Posterior Capsular Opacification

Dr. Abhishek Kumar [1*], Dr. Nupur Suman [2], Dr. Pushpalata Chaturvedi [3], Dr. Ruchi Saxena [4], Dr. Jyostna [5], Dr. Abuzar Parray [6]

[1] Department of Ophthalmology, Saraswathi Institute of Medical Science, Hapur, Uttar Pradesh, India
[2] Head of Department, Department of Ophthalmology, Saraswathi Institute of Medical Science, Hapur, Uttar Pradesh, India
[3] Associate Professor, Department of Ophthalmology, Saraswathi Institute of Medical Science, Hapur, Uttar Pradesh, India
[4] Assistant Professor, Department of Ophthalmology, Saraswathi Institute of Medical Science, Hapur, Uttar Pradesh, India
[5] Assistant Professor, Department of Ophthalmology, Saraswathi Institute of Medical Science, Hapur, Uttar Pradesh, India
[6] Department of Ophthalmology, Saraswathi Institute of Medical Science, Hapur, Uttar Pradesh, India

* Corresponding Author: **Dr. Abhishek Kumar**

Article Info

ISSN (online): 2582-8940
Volume: 06
Issue: 03
July - September 2025
Received: 08-07-2025
Accepted: 09-08-2025
Published: 22-08-2025
Page No: 228-234

Abstract

Posterior capsular opacification (PCO) is the most common long-term complication following cataract surgery, significantly impacting visual quality and necessitating Nd:YAG laser capsulotomy for treatment. This prospective study evaluated comprehensive ocular parameter changes following Nd:YAG laser capsulotomy in 150 patients with PCO. All participants underwent detailed assessment including intraocular pressure (IOP) measurement, refraction, anterior chamber depth (ACD), macular thickness analysis using optical coherence tomography (OCT), and specular microscopy at baseline and at 1 day, 1 week, 1 month, and 3 months post-procedure. Mean patient age was 68.4±8.2 years with PCO developing 18.6±12.4 months post-cataract surgery. Pre-procedure IOP was 14.2±2.8 mmHg, increasing significantly to 16.8±4.1 mmHg at 1 day (p<0.001), with gradual normalization by 1 month (14.6±3.2 mmHg, p=0.34 vs baseline). Spherical equivalent refraction showed a myopic shift from -0.12±0.68 D to -0.31±0.72 D at 1 week (p=0.02), returning to baseline by 1 month. Anterior chamber depth increased significantly from 4.18±0.42 mm to 4.24±0.44 mm at 1 week (p=0.01), remaining stable thereafter. Central macular thickness demonstrated transient increase from 243.6±18.4 μm to 251.2±22.1 μm at 1 week (p=0.006), normalizing by 1 month. Specular microscopy revealed significant endothelial cell loss with cell density decreasing from 2486±284 cells/mm² to 2398±301 cells/mm² at 3 months (3.5% reduction, p<0.001). Coefficient of variation increased from 32.4±4.8% to 35.1±5.6% (p<0.001), indicating increased pleomorphism. Hexagonality decreased from 61.2±8.4% to 58.7±9.1% (p=0.02). Visual acuity improved significantly from 0.48±0.22 logMAR pre-procedure to 0.08±0.12 logMAR at 3 months (p<0.001). Complications included transient IOP elevation >21 mmHg in 18 patients (12%), resolving with topical therapy. No cases of retinal detachment, significant inflammation, or IOL damage occurred. Laser energy positively correlated with endothelial cell loss (r=0.34, p<0.001) and IOP elevation (r=0.28, p=0.001). The study demonstrates that Nd:YAG laser capsulotomy effectively treats PCO with generally transient effects on ocular parameters, though permanent endothelial cell loss occurs. Careful patient selection, optimal laser technique, and appropriate monitoring are essential for minimizing complications while achieving excellent visual outcomes.

DOI: https://doi.org/10.54660/IJMBHR.2025.6.3.228-234

Keywords: Nd:YAG Laser Capsulotomy, Posterior Capsular Opacification, Intraocular Pressure, Endothelial Cell Loss, Macular Thickness, Anterior Chamber Depth, Cataract Surgery Complications, Specular Microscopy

Introduction

Posterior capsular opacification (PCO) represents the most frequent long-term complication following cataract surgery, occurring in 20-40% of patients within 2-5 years of phacoemulsification [1]. This condition results from proliferation, migration and trans differentiation of residual lens epithelial cells on the posterior lens capsule, leading to visual symptoms including, decreased visual acuity, glare, contrast sensitivity reduction, and subjective visual quality deterioration [2]. The pathophysiology involves epithelial-mesenchymal transition of lens epithelial cells, extracellular matrix deposition, and capsular wrinkling, collectively creating optical barriers that significantly impact visual function [3].

Neodymium:yttrium-aluminum-garnet (Nd:YAG) laser posterior capsulotomy has become the standard treatment for clinically significant PCO since its introduction in the 1980s [4]. This non-invasive procedure utilizes short-pulsed infrared laser energy (1064 nm wavelength) to create photodisruption of the opacified posterior capsule, thereby restoring optical clarity and improving visual function [5]. The mechanism involves plasma formation and acoustic shock wave generation, resulting in precise tissue cutting without thermal damage to surrounding structures [6].

While Nd:YAG laser capsulotomy is generally considered safe and effective, various complications and secondary effects have been reported, necessitating comprehensive evaluation of ocular parameter changes following the procedure [7]. Intraocular pressure elevation represents one of the most common acute complications, occurring in 15-30% of patients within hours to days post-procedure [8]. The mechanism involves inflammatory mediator release, debris-induced trabecular meshwork obstruction, and potential pupillary block from capsular fragments [9].

Refractive changes following Nd:YAG capsulotomy have been inconsistently reported, with some studies demonstrating myopic shifts attributed to anterior chamber deepening, while others report minimal refractive impact [10]. The potential mechanisms include IOL position changes, effective lens position alterations, and induced astigmatism from capsular tension modifications [11]. Understanding these refractive implications is crucial for patient counseling and managing visual expectations post-procedure.

Anterior chamber depth changes represent another parameter of interest, as capsular disruption may alter IOL stability and position [12]. The posterior capsule provides structural support for IOL centration and stability, and its disruption through laser capsulotomy may theoretically affect anterior chamber dimensions [13]. Additionally, inflammatory responses and aqueous humor dynamics changes could contribute to anterior chamber depth variations.

Macular changes following Nd:YAG laser capsulotomy have gained increasing attention with the advent of optical coherence tomography (OCT) technology [14]. Cystoid macular edema (CME) represents a potentially serious complication, occurring in 0.5-4% of patients post-capsulotomy [15]. The pathogenesis involves inflammatory mediator release, blood-retinal barrier disruption, and prostaglandin-mediated vascular permeability increases [16]. Subclinical macular thickness changes may occur more frequently than clinically apparent CME, highlighting the importance of OCT monitoring.

Corneal endothelial cell damage represents a significant concern given the limited regenerative capacity of the corneal endothelium [17]. Nd:YAG laser energy can cause mechanical trauma to endothelial cells through shock wave propagation, inflammatory mediator exposure, and potential direct energy absorption [18]. Specular microscopy provides detailed assessment of endothelial cell density, morphology, and functional parameters, enabling quantification of laser-induced endothelial damage [19].

The relationship between laser parameters and complication rates has been extensively studied, with higher energy levels generally associated with increased adverse effects [20]. Optimal capsulotomy size, laser spot placement, and energy titration remain subjects of ongoing research aimed at maximizing efficacy while minimizing complications [21]. Patient factors including age, IOL type, capsular opacity density, and pre-existing ocular conditions may influence both treatment response and complication risk [22].

Contemporary IOL designs incorporating square-edge technology and enhanced biocompatibility have significantly reduced PCO incidence compared to earlier lens designs [23]. However, PCO remains a clinically relevant problem requiring ongoing management strategies. The timing of capsulotomy intervention represents a balance between symptom severity, visual function impact, and potential procedural risks [24].

This comprehensive study aims to evaluate multiple ocular parameters following Nd:YAG laser capsulotomy, providing detailed analysis of IOP changes, refractive alterations, anterior chamber depth modifications, macular thickness variations, and corneal endothelial cell responses. By examining these parameters longitudinally, we seek to enhance understanding of capsulotomy effects and optimize patient management strategies.

Materials and Methods

Study Design and Participants

This prospective, observational study was conducted at the Department of Ophthalmology from January 2023 to December 2023, following approval from the Institutional Review Board and adherence to the Declaration of Helsinki principles. Written informed consent was obtained from all participants prior to enrollment.

A total of 150 patients with visually significant posterior capsular opacification requiring Nd:YAG laser capsulotomy were enrolled. Inclusion criteria included: age 50-85 years, previous uncomplicated phacoemulsification with posterior chamber IOL implantation, clinically significant PCO causing visual symptoms, best-corrected visual acuity ≤20/40 due to PCO, and ability to complete follow-up examinations. Exclusion criteria comprised: complicated cataract surgery, vitreoretinal pathology, glaucoma, corneal disease, uveitis, diabetic retinopathy, age-related macular degeneration, and inability to undergo reliable testing.

Preoperative Assessment

Comprehensive ophthalmic examination was performed including: best-corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts, slit-lamp biomicroscopy with PCO grading using the Evaluation of Posterior Capsule Opacification (EPCO) system [25], intraocular pressure measurement using Goldmann applanation tonometry, and dilated fundoscopy.

Optical biometry was performed using the IOLMaster 700 (Carl Zeiss Meditec, Jena, Germany) to measure anterior chamber depth, axial length, and keratometry. Automated refraction was obtained using the KR-8900 autorefractor (Topcon Corporation, Tokyo, Japan), followed by subjective refraction to determine spherical equivalent.

Macular OCT imaging was performed using the Heidelberg Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany) with a standardized 20°×20° volume scan protocol. Central macular thickness, macular volume, and retinal layer segmentation were analyzed using the device software.

Corneal specular microscopy was performed using the SP-1P specular microscope (Topcon Corporation, Tokyo, Japan) to assess endothelial cell density, coefficient of variation (CV), and hexagonality percentage. Multiple images were captured from the central cornea and averaged for analysis.

Laser Capsulotomy Procedure

All procedures were performed by experienced ophthalmologists using the Nd:YAG laser (VISULAS YAG III, Carl Zeiss Meditec, Jena, Germany). Pre-procedure preparation included instillation of topical anesthesia (proparacaine 0.5%) and miosis induction using pilocarpine 2% to protect the peripheral retina.

A Abraham capsulotomy lens was used for optimal visualization and laser delivery. The capsulotomy was performed using a cruciate pattern with initial vertical and horizontal cuts, followed by additional radial cuts as needed to create a central opening of approximately 4-5 mm diameter. Initial energy settings were 1.0-1.5 mJ per pulse, with titration based on capsular response. Total energy delivered and number of pulses were recorded for each procedure.

Post-procedure topical therapy included prednisolone acetate 1% four times daily for one week, followed by twice daily for an additional week. Patients with significant IOP elevation received additional anti-glaucoma medications as indicated.

Follow-up Protocol

Patients were examined at 1 day, 1 week, 1 month, and 3 months post-procedure. Each visit included measurement of IOP, visual acuity assessment, slit-lamp examination, and evaluation for complications. Complete OCT, specular microscopy, and biometry were repeated at 1 week, 1 month, and 3 months.

Outcome Measures

Primary outcome measures included: changes in IOP, spherical equivalent refraction, anterior chamber depth, central macular thickness, and corneal endothelial cell parameters. Secondary outcomes included: visual acuity improvement, complication rates, and correlations between laser parameters and ocular changes.

Statistical Analysis

Statistical analysis was performed using SPSS version 28.0 (IBM Corporation, Armonk, NY). Normality of data distribution was assessed using the Kolmogorov-Smirnov test. Continuous variables were expressed as mean ± standard deviation, and categorical variables as frequencies and percentages.

Repeated measures ANOVA was used to analyze parameter changes over time, with Bonferroni correction for multiple comparisons. Paired t-tests were used for specific time point comparisons. Pearson correlation coefficients were calculated to assess relationships between laser parameters and outcome measures. A p-value <0.05 was considered statistically significant.

Results

Demographics and Baseline Characteristics

The study included 150 patients with a mean age of 68.4±8.2 years (range: 52-84 years). The cohort consisted of 82 females (54.7%) and 68 males (45.3%). Mean time from cataract surgery to PCO development was 18.6±12.4 months (range: 6-48 months). IOL types included monofocal acrylic (n=124, 82.7%), monofocal silicone (n=18, 12.0%), and multifocal (n=8, 5.3%).

Table 1: Demographics and Baseline Characteristics

Parameter	Value	Range
Age (years)	68.4±8.2	52-84
Gender (Female/Male)	82/68 (54.7%/45.3%)	-
Time to PCO (months)	18.6±12.4	6-48
EPCO Grade 1-2/3-4	89/61 (59.3%/40.7%)	-
Baseline BCVA (logMAR)	0.48±0.22	0.18-1.00
Laser Energy (mJ)	47.8±18.6	15-95
Number of Pulses	28.4±12.1	8-65

EPCO: Evaluation of Posterior Capsule Opacification; BCVA: Best-corrected visual acuity

Intraocular Pressure Changes

Baseline IOP was 14.2±2.8 mmHg, increasing significantly to 16.8±4.1 mmHg at 1-day post-procedure (p<0.001). Peak IOP elevation occurred within 24 hours in most patients, with gradual normalization observed over subsequent visits. At 1 week, mean IOP was 15.4±3.6 mmHg (p=0.008 vs baseline), normalizing to 14.6±3.2 mmHg at 1 month (p=0.34 vs baseline) and 14.3±2.9 mmHg at 3 months (p=0.82 vs baseline).

Clinically significant IOP elevation (>21 mmHg) occurred in 18 patients (12%) at 1 day, with all cases responding to topical anti-glaucoma therapy. No patients required surgical intervention for IOP control.

Table 2: Intraocular Pressure Changes Over Time

Time Point	IOP (mmHg)	P-value vs Baseline	Patients >21 mmHg
Baseline	14.2±2.8	-	0 (0%)
1 Day	16.8±4.1	<0.001*	18 (12%)
1 Week	15.4±3.6	0.008*	4 (2.7%)
1 Month	14.6±3.2	0.34	1 (0.7%)
3 Months	14.3±2.9	0.82	0 (0%)

*Statistically significant (p<0.05)

Refractive Changes
Spherical equivalent refraction showed a mild myopic shift from baseline -0.12±0.68 D to -0.25±0.71 D at 1 day (p=0.08), reaching significance at 1 week (-0.31±0.72 D, p=0.02). The myopic shift gradually resolved, with values returning to baseline levels by 1 month (-0.18±0.69 D, p=0.42) and 3 months (-0.14±0.67 D, p=0.78).
Cylindrical power showed minimal changes throughout the follow-up period, with no statistically significant alterations observed (p>0.05 for all time points).

Anterior Chamber Depth Changes
Baseline anterior chamber depth was 4.18±0.42 mm, showing a significant increase to 4.24±0.44 mm at 1 week (p=0.01). This deepening persisted at 1 month (4.23±0.43 mm, p=0.02) and 3 months (4.22±0.42 mm, p=0.03), indicating permanent structural changes following capsulotomy.

Macular Thickness Analysis
Central macular thickness demonstrated transient increases from baseline 243.6±18.4 µm to 248.3±20.2 µm at 1 day (p=0.03) and 251.2±22.1 µm at 1 week (p=0.006). Values normalized by 1 month (245.8±19.7 µm, p=0.28) and remained stable at 3 months (244.2±18.9 µm, p=0.76).
Three patients (2%) developed clinically apparent cystoid macular edema, all resolving with topical anti-inflammatory therapy within 6 weeks.

Table 3: Macular and Anterior Chamber Changes

Parameter	Baseline	1 Week	1 Month	3 Months
CMT (µm)	243.6±18.4	251.2±22.1*	245.8±19.7	244.2±18.9
ACD (mm)	4.18±0.42	4.24±0.44*	4.23±0.43*	4.22±0.42*
SE (D)	-0.12±0.68	-0.31±0.72*	-0.18±0.69	-0.14±0.67

*Statistically significant compared to baseline (p<0.05) CMT: Central macular thickness; ACD: Anterior chamber depth; SE: Spherical equivalent

Specular Microscopy Results
Corneal endothelial cell density decreased significantly from baseline 2486±284 cells/mm² to 2398±301 cells/mm² at 3 months, representing a 3.5% reduction (p<0.001). Cell loss was most pronounced within the first month, with minimal additional loss between 1 and 3 months.
Coefficient of variation increased from 32.4±4.8% to 35.1±5.6% at 3 months (p<0.001), indicating increased pleomorphism. Hexagonality decreased from 61.2±8.4% to 58.7±9.1% (p=0.02), suggesting altered cell morphology.

Table 4: Corneal Endothelial Cell Parameters

Parameter	Baseline	1 Month	3 Months	P-value
Cell Density (cells/mm²)	2486±284	2428±296*	2398±301*	<0.001
CV (%)	32.4±4.8	34.2±5.3*	35.1±5.6*	<0.001
Hexagonality (%)	61.2±8.4	59.8±8.9	58.7±9.1*	0.02
Cell Loss (%)	-	2.3±1.8	3.5±2.4	-

*Statistically significant compared to baseline (p<0.05) CV: Coefficient of variation

Visual Outcomes
Best-corrected visual acuity improved dramatically from 0.48±0.22 logMAR pre-procedure to 0.12±0.15 logMAR at 1 day (p<0.001), 0.09±0.13 logMAR at 1 week (p<0.001), 0.08±0.12 logMAR at 1 month (p<0.001), and 0.08±0.12 logMAR at 3 months (p<0.001). Final visual acuity of 20/25 or better was achieved in 132 patients (88%).

Correlations and Risk Factors
Total laser energy positively correlated with endothelial cell loss (r=0.34, p<0.001), peak IOP elevation (r=0.28, p=0.001), and macular thickness increase (r=0.22, p=0.007). Patient age correlated with greater endothelial cell loss (r=0.19, p=0.02) but not with other parameters.



Fig 1A: IOP changes over time by treatment group



Fig 1B: Endothelial cell density changes



Fig 2A: Correlation between laser energy and cell loss



Fig 2B: Visual acuity improvement over time

Discussion

This comprehensive study provides detailed analysis of multiple ocular parameter changes following Nd:YAG laser capsulotomy, contributing valuable insights into the safety profile and efficacy of this common procedure [26]. Our findings demonstrate that while capsulotomy effectively treats PCO with excellent visual outcomes, various transient and permanent changes occur in ocular structures that require careful monitoring and patient counseling.

The transient IOP elevation observed in our study, with peak values occurring within 24 hours post-procedure, aligns with previous reports and reflects the inflammatory response to laser treatment [27]. The 12% incidence of clinically significant IOP elevation (>21 mmHg) falls within the reported range of 10-30% in the literature. The mechanism involves inflammatory mediator release, debris-induced trabecular obstruction, and aqueous outflow compromise. Importantly, all cases responded to topical anti-glaucoma therapy without requiring surgical intervention, supporting the generally manageable nature of this complication.

The mild myopic shift observed at 1 week, with subsequent return to baseline, likely reflects temporary anterior chamber deepening and inflammatory changes affecting effective lens position [28]. This finding has important implications for patients considering refractive procedures or IOL exchanges, as timing relative to capsulotomy may influence outcomes. The permanent increase in anterior chamber depth of approximately 0.06 mm suggests structural alterations following capsular disruption, possibly related to IOL position changes or capsular bag dynamics.

Our macular thickness analysis revealed transient increases peaking at 1 week post-procedure, with 2% of patients developing clinically apparent CME. These findings emphasize the importance of OCT monitoring, particularly in high-risk patients such as those with diabetes or previous macular pathology [29]. The subclinical macular thickness changes observed in the majority of patients suggest that inflammatory responses are more common than clinically apparent, supporting the routine use of anti-inflammatory prophylaxis.

The corneal endothelial cell loss of 3.5% at 3 months represents a significant concern given the limited regenerative capacity of the corneal endothelium. While this magnitude of cell loss is unlikely to cause immediate corneal decompensation in healthy corneas, the cumulative effect of multiple procedures or pre-existing endothelial compromise could be clinically significant. The positive correlation between laser energy and cell loss underscores the importance of using minimal effective energy levels and optimizing laser technique to minimize endothelial damage.

The morphological changes in endothelial cells, including increased pleomorphism (higher CV) and reduced hexagonality, suggest that surviving cells undergo stress-related alterations beyond simple cell loss. These changes may compromise endothelial function even when cell density remains adequate, highlighting the need for long-term monitoring in patients undergoing capsulotomy.

Visual outcomes in our study were excellent, with 88% of patients achieving 20/25 or better visual acuity, confirming the efficacy of Nd:YAG capsulotomy for treating visually significant PCO. The dramatic improvement from 0.48 to 0.08 logMAR represents a clinically meaningful enhancement in visual function that significantly impacts quality of life. These results support the continued use of laser capsulotomy as the standard treatment for PCO.

The correlation between laser energy and adverse effects highlights the importance of optimizing laser parameters to minimize complications while maintaining efficacy. Factors influencing optimal energy selection include capsular opacity density, IOL material, anterior chamber depth, and individual tissue response characteristics. The use of modern laser systems with improved beam profiles and energy delivery may further reduce complication rates.

Several limitations of our study should be acknowledged. The 3-month follow-up period may not capture late complications such as retinal detachment, which can occur months to years post-procedure. Additionally, our exclusion criteria may have selected a lower-risk population, potentially underestimating complication rates in real-world practice. The lack of a control group limits our ability to distinguish procedure-related changes from natural aging effects.

Clinical implications of our findings include the importance of comprehensive pre-procedure counseling regarding potential complications, particularly endothelial cell loss in patients with marginal corneal function. Post-procedure monitoring should include IOP assessment within 24 hours, particularly in patients at risk for glaucoma. Routine OCT monitoring may be beneficial in high-risk patients, and specular microscopy should be considered in patients with pre-existing endothelial compromise.

Future research directions should include longer-term follow-up studies to assess the durability of outcomes and late complication rates. Investigation of protective strategies to minimize endothelial cell loss, such as modified laser parameters or pharmacological interventions, could improve safety profiles. Additionally, development of predictive models for complication risk could enhance patient selection and treatment planning.

Conclusion

This comprehensive evaluation of ocular parameters following Nd:YAG laser capsulotomy demonstrates that the procedure effectively treats posterior capsular opacification with excellent visual outcomes while causing various transient and permanent ocular changes. The study confirms that most complications are mild and transient, including temporary IOP elevation, refractive changes, and macular thickness alterations, all of which typically resolve within one month with appropriate management.

However, the significant finding of permanent corneal endothelial cell loss of 3.5% at three months, accompanied by morphological changes indicating cellular stress, represents an important consideration for patient counseling and long-term monitoring. The positive correlation between laser energy and endothelial cell loss emphasizes the critical importance of using optimal laser parameters to minimize tissue damage while maintaining therapeutic efficacy.

The excellent visual outcomes achieved, with 88% of patients attaining 20/25 or better visual acuity, strongly support the continued use of Nd:YAG laser capsulotomy as the gold standard treatment for visually significant PCO. The dramatic improvement in visual function from 0.48 to 0.08 logMAR represents a clinically meaningful enhancement that significantly impacts patient quality of life and functional vision.

Key clinical recommendations emerging from this study include comprehensive pre-procedure patient counseling regarding potential complications, particularly for patients with marginal corneal endothelial function; routine IOP monitoring within 24 hours post-procedure; consideration of OCT monitoring in high-risk patients for macular edema detection; and long-term specular microscopy follow-up in patients with pre-existing corneal compromise. The use of minimal effective laser energy and optimal technique remains paramount for maximizing benefits while minimizing adverse effects.

This research contributes valuable quantitative data to the existing literature on Nd:YAG laser capsulotomy outcomes and provides evidence-based guidance for optimizing patient care. The findings will assist clinicians in making informed decisions regarding treatment timing, patient selection, and post-procedure monitoring protocols, ultimately improving patient outcomes and safety in this common ophthalmic procedure.

References

1. Awasthi N, Guo S, Wagner BJ. Posterior capsular opacification: a problem reduced but not yet eradicated. Arch Ophthalmol. 2009;127(4):555-62.
2. Marcantonio JM, Vrensen GF. Cell biology of posterior capsular opacification. Eye (Lond). 1999;13(Pt 3b):484-8.
3. Wormstone IM, Wang L, Liu CS. Posterior capsule opacification. Exp Eye Res. 2009;88(2):257-69.
4. Aron-Rosa D, Aron JJ, Griesemann M, Thyzel R. Use of the neodymium-YAG laser to open the posterior capsule after lens implant surgery: a preliminary report. J Am Intraocul Implant Soc. 1980;6(4):352-4.
5. Bath PE, Fankhauser F. Long-term results of Nd-YAG laser posterior capsulotomy with the Swiss laser. J Cataract Refract Surg. 1986;12(2):150-3.
6. Vogel A, Noack J, Hüttman G, Paltauf G. Mechanisms of femtosecond laser nanosurgery of cells and tissues. Appl Phys B. 2005;81(8):1015-47.
7. Javitt JC, Tielsch JM, Canner JK, Kolb MM, Sommer A, Steinberg EP. National outcomes of cataract extraction. Increased risk of retinal complications associated with Nd:YAG laser capsulotomy. Ophthalmology. 1992;99(10):1487-97.
8. Ge J, Wand M, Chiang R, Paranhos A, Shields MB. Long-term effect of Nd:YAG laser posterior capsulotomy on intraocular pressure. Arch Ophthalmol. 2000;118(10):1334-7.
9. Slomovic AR, Parrish RK. Acute elevations of intraocular pressure following Nd:YAG laser posterior capsulotomy. Ophthalmology. 1985;92(7):973-6.
10. Hayashi K, Hayashi H, Nakao F, Hayashi F. Changes in anterior chamber angle width and depth after intraocular lens implantation in eyes with glaucoma. Ophthalmology. 2000;107(4):698-703.
11. Freedman KA, Jampel HD, Threlkeld AB, Quigley HA, Green RL. Effects of posterior capsular opacification on the retinal nerve fiber layer and optic disc topography. J Glaucoma. 2003;12(4):307-11.
12. Werner L, Tassignon MJ, Zaugg B, Rönbeck M, Picó AR. Anterior capsule opacification: correlation of pathologic findings with clinical sequelae. Ophthalmology. 2018;125(7):1016-26.
13. Nishi O, Nishi K, Wickstrom K. Preventing lens epithelial cell migration using intraocular lenses with sharp rectangular edges. J Cataract Refract Surg. 2000;26(10):1543-9.
14. Falcão MS, Gonçalves NM, Freitas-Costa P, Beato JN, Rocha-Sousa A, Falcão-Reis F. Choroidal and macular thickness changes induced by cataract surgery. Clin Ophthalmol. 2014;8:55-60.
15. Stark WJ Jr, Worthen D, Holladay JT, Murray G. Neodymium:YAG lasers. An FDA report. Ophthalmology. 1985;92(2):209-12.
16. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002;47 Suppl 1:S203-18.
17. Bourne WM, Nelson LR, Hodge DO. Central corneal endothelial cell changes over a ten-year period. Invest Ophthalmol Vis Sci. 1997;38(3):779-82.
18. Steinert RF, Puliafito CA, Kumar SR, Dudak SD, Patel S. Cystoid macular edema, retinal detachment, and glaucoma after Nd:YAG laser posterior capsulotomy. Am J Ophthalmol. 1991;112(4):373-80.
19. Doughty MJ, Zaman ML. Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol. 2000;44(5):367-408.
20. Terry AC, Stark WJ, Maumenee AE, Fagadau W. Neodymium-YAG laser for posterior capsulotomy. Am J Ophthalmol. 1983;96(6):716-20.
21. Qureshi MH, Steel DH. Retinal detachment following Nd:YAG laser posterior capsulotomy. Eye (Lond). 2020;34(8):1364-9.
22. Schaumberg DA, Dana MR, Christen WG, Glynn RJ. A systematic overview of the incidence of posterior capsule opacification. Ophthalmology. 1998;105(7):1213-21.
23. Nishi O, Nishi K, Sakanishi K. Inhibition of migrating lens epithelial cells at the capsular bend created by the rectangular optic edge of a posterior chamber intraocular lens. Ophthalmic Surg Lasers. 1998;29(7):587-94.
24. Apple DJ, Solomon KD, Tetz MR, *et al*. Posterior capsule opacification. Surv Ophthalmol. 1992;37(2):73-116.
25. Tetz MR, Auffarth GU, Sperker M, Blum M, Völcker HE. Photographic image analysis system of posterior capsule opacification. J Cataract Refract Surg. 1997;23(10):1515-20.
26. Karahan E, Tuncer I, Zengin MO. The effect of ND:YAG laser posterior capsulotomy size on refraction, intraocular pressure, and macular thickness. J Ophthalmol. 2014;2014:846385.
27. Burnett J, Davison J, Gills J, *et al*. Clinical evaluation of the YAG laser for posterior capsulotomy in pseudophakic patients. J Am Intraocul Implant Soc. 1984;10(3):319-23.
28. Kraff MC, Sanders DR, Lieberman HL. Specular microscopy in cataract and intraocular lens patients. A report of 564 cases. Arch Ophthalmol. 1980;98(10):1782-4.
29. Benhamou N, Massin P, Haouchine B, Erginay A, Gaudric A. Macular edema after cataract surgery: role of early angiography and treatment. Ophthalmology. 2003;110(1):146-52.